Introduction {#sec1-1}
============

The eye is typically resistant to primary infection due to the numerous cellular and molecular elements that protect the corneal surface against microorganisms. These elements include tears, corneal nerves, the epithelium, keratocytes, polymorphonuclear cells, and cytokines (Akpek and Gottsch, 2003). The presence of tears is of particular importance since, besides preventing the cornea from drying, it also helps flush foreign particles from the ocular surface and transports antimicrobial proteins (lactoferrin, lysozyme, lipocalin, and beta-lysin) and immunoglobulins to the ocular surface to prevent infections (Mannis and Smolin, 1996). As a consequence of all these factors, with the exception of the herpesviruses and infection with *Moraxella bovis*, microorganisms cannot initiate primary keratitis in animals (Maggs, 2008).

Considering, septic ocular surface disease typically requires an initial injury, such as mechanical or chemical trauma, before a microorganism can infect the cornea (Mayo *et al.*, 1986). Specifically, bacterial infections of ocular surfaces are commonly the result of a predisposing factor or disease that allows the overgrowth of a bacterium that is or is not a part of the ocular surface microbiota (Quinn *et al.*, 1994; Moore *et al*. 1995; Ledbetter *et al.*, 2009).

*Pseudomonas* *aeruginosa*, a gram-negative bacillus that is widely distributed in nature, is commonly considered a transitional opportunistic agent and part of the normal ocular surface microbiota (Quinn *et al.*, 1994). However, *P. aeruginosa* is also frequently isolated from ocular surface infections, especially from ocular septic keratitis (Ledbetter *et al.*, 2009). This microorganism is considered one of the most destructive bacteria associated with eye infections in any species (Gutierrez, 1972), having a variety of mechanisms and virulence factors which allow efficient colonization and subsequently compromised ocular tissues and most corneal layers. Examples of such factors include bacterial proteases, and an exotoxin that can destroy epithelial and endothelial cells within 24 hours.

Hemolysins also contribute to *P*. *aeruginosa's* invasiveness, tissue destruction and efficient colonization of ocular tissues (Gutierrez, 1972; Moore *et al.*, 1995; Carter, 1999). Finally, the pigment pyocyanin may also contribute to tissue damage by inhibiting cellular oxygen uptake (Moore *et al.*, 1995).

Treatment of ocular surface infections where *P. aeruginosa* is isolated requires aggressive topical antibiotic therapy (Moore and Naisse, 2000).

However, over time it can be expected that ocular infections become less responsive to antibiotics due to the emergence of resistant bacterial strains. Therefore, it becomes important to implement a strategy for monitoring the emergence and spread of resistance. Antimicrobial susceptibility tests are an indispensable method to determine the most effective antibiotics for the treatment of eye infections.

The Kirby--Bauer disk diffusion test is the routine laboratory test used to determine antimicrobial susceptibility and it is crucial for veterinary ophthalmologists to provide an appropriate antimicrobial therapy (Moore *et al.*, 1995).

Minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial drug that will inhibit visible growth of a microorganism after incubation. Since it is a quantitative way to measure the susceptibility of an organism to an antimicrobial, MIC is considered an important tool for confirming resistance of microorganisms to a given antimicrobial agent (Andrews, 2001; CDC, 2002). This is particularly true for ocular surface infections, where a drug can be delivered directly to the site of infection at a high concentration compared to that of systemic intravenous administration (Levison and Levison, 2009).

Due to the aggressive nature of *P. aeruginosa* infections and the devastating consequences they can have on the eye, the lag time between diagnosis and antimicrobial susceptibility test results might enable significant and irreversible damage to be done to the eye prior to initiation of proper therapy. Epidemiological data of general susceptibility patterns may be helpful in certain situations such as when empiric rational therapy is indicated. The purpose of the present study was twofold: 1) investigate *in vitro* antibiotic susceptibilities by disc-diffusion of a panel of 11 antibiotics, and 2) investigate the minimal inhibitory concentrations of tobramycin and ciprofloxacin (two of the most commonly used topical antibiotics used for ocular surface infection) against naturally occurring *P. aeruginosa* ocular surface infections of dogs, cats, horses as well as two never before reported species, the Magellanic penguin and the brown bear.

Materials and Methods {#sec1-2}
=====================

Specimen collection {#sec2-1}
-------------------

This study included sixteen (n=16) clinical isolates of *P. aeruginosa* from various species of animals presenting to the Comparative Ophthalmology Service at The Federal University of Paraná, Brazil with ocular surface infections (conjunctival, corneal or conjunctival and corneal). All the procedures using animals were conducted in accordance with the humane principles set forth in the ARVO Statement (Association for Research in Vision and Ophthalmology) for the Use of Animals in Ophthalmic and Vision Research and in accordance with UFPR´s (Universidade Federal do Paraná) Animal Use Committee.

All animals were first examined for signs of ophthalmic or general clinical disease. A complete ocular examination, including slit lamp biomicroscopy (Hawk Eye; Dioptrix, L'Union, France), indirect ophthalmoscopy (Heine EN20-01 indirect ophthalmoscope; Heine Optotechnik, Herrsching, Germany), rebound tonometry (TonoVet tonometer; ICare Finland Oy, Helsinki, Finland), fluorescein staining (Drogavet; Curitiba-PR, Brazil), and Schirmer tear testing (Drogavet; Curitiba-PR, Brazil) was performed on each animal. Only animals presenting with signs of ocular surface infections without signs of uveitis, glaucoma, or systemic disease and with no history of having received systemic or topical ophthalmic antimicrobials in the preceding 30 days were included in the study.

Bacterial identification {#sec2-2}
------------------------

A sterile cotton swab was used to gently sample the corneal and conjunctival surfaces of each infected eye. Swabs were then removed while taking care to avoid contact with eyelashes or skin of the eyelids. The swabs were kept in Stuart´s transport medium, placed on ice and transported within 24 hours for microbiology culture. Swabs were plunged in BHI broth (brain heart infusion), an enrichment medium, for 24 hours at 37°C. The enrichment cultures were then streaked onto 5% Sheep Blood agar (Newprov®, Curitiba, Brazil).

Animals with signs of ocular surface infections in which *P. aeruginosa* was isolated were deemed to met all the inclusion criteria. Positive bacterial colonies were replicated in selective and differential media for Gram-negative bacteria (MacConkey agar and Brilliant Green agar). *P. aeruginosa* strains were confirmed by their Gram stain reaction, characteristic colonial morphology, oxidase production, motility and pyocyanin production (Quinn *et al.*, 1994; Carter, 1999).

Subsequently, only the cases of ocular surface infections where *P. aeruginosa* was isolated were included. Different animal species that fit this criterion were: dogs (*Canis familiaris*) (n=10), horses (*Equus caballus*) (n=3), cat (*Felis catus*) (n=1), brown bear (*Ursus arctos*) (n=1) and a Magellanic penguin (*Spnenicus megellanucus*) (n=1). Ocular surface diseases diagnosed in these animals were: Corneal ulcers (n=7); Keratoconjunctivitis sicca (n=5); Blepharoconjunctivits (n=4). [Table 1](#T1){ref-type="table"} summarizes and further details the ocular surface diseases diagnosed in each animal species studied.

###### 

List of animal species and ocular diseases from which *P. aeruginosa* was isolated.

  Sample identification   Animal species                                Ocular diagnosis
  ----------------------- --------------------------------------------- -------------------------------------
  1                       Dog                                           Corneal ulcer
  2                       Dog                                           Oronasal fistula + conjunctivitis
  3                       Dog                                           KCS[\*](#t1f1){ref-type="table-fn"}
  4                       Dog                                           Corneal ulcer
  5                       Dog                                           Corneal ulcer
  6                       Dog                                           KCS[\*](#t1f1){ref-type="table-fn"}
  7                       Dog                                           KCS[\*](#t1f1){ref-type="table-fn"}
  8                       Dog                                           Oronasal fistula + conjunctivitis
  9                       Dog                                           KCS[\*](#t1f1){ref-type="table-fn"}
  10                      Dog                                           KCS[\*](#t1f1){ref-type="table-fn"}
  11                      Cat                                           Corneal ulcer
  12                      Horse                                         Corneal ulcer
  13                      Horse                                         Corneal ulcer
  14                      Penguim^[1](#t1f2){ref-type="table-fn"}^      Conjunctivitis
  15                      Brown Bear^[2](#t1f3){ref-type="table-fn"}^   Conjunctivitis
  16                      Horse                                         Corneal ulcer

keratoconjunctivitis sicca.

*Spnenicus* *megellanucus.*

Ursus arctos.

Susceptibility tests {#sec2-3}
--------------------

Antimicrobial sensitivity of the isolated *P. aeruginosa* strains was determined by the disk-diffusion technique (also known as Kirby-Bauer method, one of the oldest approaches to antimicrobial susceptibility testing, in which is used Mueller-Hinton agar plates and it is used the direct colony suspension method to make a suspension of the organism in saline to the density of a McFarland 0.5 turbidity standard), in compliance with the National Committee for Clinical and Laboratory Standards (CLSI) (2013) criteria or European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2013). Isolates whose antibiogram yielded intermediate results were considered resistant. Eleven (11) available antimicrobial discs (Newprov®, Curitiba, Brazil) were used: enrofloxacin (10µg), ciprofloxacin (5μg), norfloxacin (10µg), gatifloxacin (10µg), tobramycin (10µg), gentamicin (10μg), amikacin (30µg), streptomycin (10µg), neomycin (30µg), imipenem (10gµ), polymyxin B (300U).

All the strains were tested to the minimal inhibitory concentration (MIC) test for tobramycin (antibiotic strip impregnated with the antibiotic and in which the concentration ranged from 0.016-128 µg/ml) and ciprofloxacin (antibiotic strip impregnated with the antibiotic and in which the concentration tested ranged from 0.002 -- 32 µg/ml), using a commercially available strip antibiotic test (E-test, AB Biodisk®, Sweden). Etest® is a rapid and well-established method for antimicrobial resistance testing.

It consists of a predefined gradient of antibiotic concentrations on a plastic strip that carries a continuous concentration gradient of stabilized and dried drug. The intersection of the inhibitory zone with the strip is the MIC. The zone of inhibition was interpreted and classified as sensible, resistant and intermediate according to the manufacturer's manual (E-test, AB Biodisk®, Sweden). It was used Mueller-Hinton agar plates and used the direct colony suspension method to make a suspension of the organism in a saline solution to the density of a McFarland 0.5 turbidity standard. The MIC breakpoints were determined according to CLSI (2013) guidelines: CIP, ciprofloxacin (S≤1; I 2; R≥4); TOB, tobramycin (S≤4; I 8; R≥16); intermediate results were considered resistant. *P. aeruginosa* ATCC 27853 was used as quality control.

Results {#sec1-3}
=======

Typical signs encountered in the animals with septic ocular surface disease included blepharospasm, ocular discharge, conjunctival venous congestion and hyperemia, chemosis, low Schirmer tear test results, and corneal malacia, opacification, edema, neovascularization and ulceration. Imipenen was the only drug to which 100% of *P. aeruginosa* strains showed *in vitro* susceptibility in this study. A high susceptibility rate (87.5%) was demonstrated to amikacin, followed by gentamicin, norfloxacin, gatifloxacin and polymyxin (81.5%) and a low susceptibility rate to enrofloxacin (25%). Results for all antibiotics tested are summarized in [Table 2](#T2){ref-type="table"} and the breakpoints used to definy the strains as susceptiple or resistant were according CLSI (2013) guidelines.

###### 

Antimicrobial susceptibility patterns of *P. aeruginosa* isolated from eyes of different species of animals.

  Drugs^[a](#t2f1){ref-type="table-fn"}^/sample   1^[b](#t2f2){ref-type="table-fn"}^   2^[b](#t2f2){ref-type="table-fn"}^   3^[b](#t2f2){ref-type="table-fn"}^   4^[b](#t2f2){ref-type="table-fn"}^   5^[b](#t2f2){ref-type="table-fn"}^   6^[b](#t2f2){ref-type="table-fn"}^   7^[b](#t2f2){ref-type="table-fn"}^   8^[b](#t2f2){ref-type="table-fn"}^   9^[b](#t2f2){ref-type="table-fn"}^   10^[b](#t2f2){ref-type="table-fn"}^   11^[c](#t2f3){ref-type="table-fn"}^   12^[d](#t2f4){ref-type="table-fn"}^   13^[d](#t2f4){ref-type="table-fn"}^   14^[e](#t2f5){ref-type="table-fn"}^   15^[f](#t2f6){ref-type="table-fn"}^   16^[d](#t2f4){ref-type="table-fn"}^   S %     R%
  ----------------------------------------------- ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------- -------
  ENO                                             S                                    R                                    R                                    S                                    S                                    R                                    R                                    R                                    R                                    R                                     R                                     R                                     S                                     R                                     R                                     R                                     25      75
  CIP                                             R                                    S                                    S                                    S                                    S                                    R                                    S                                    S                                    S                                    S                                     R                                     S                                     S                                     S                                     S                                     R                                     75      25
  NOR                                             S                                    S                                    S                                    S                                    S                                    R                                    S                                    S                                    S                                    S                                     S                                     R                                     S                                     S                                     S                                     R                                     81.25   18.75
  GAT                                             S                                    S                                    S                                    S                                    S                                    R                                    S                                    S                                    S                                    S                                     R                                     S                                     S                                     S                                     S                                     R                                     81.25   18.75
  TOB                                             R                                    S                                    S                                    S                                    S                                    R                                    S                                    S                                    S                                    S                                     R                                     R                                     S                                     S                                     S                                     R                                     68.75   31.25
  GEN                                             S                                    S                                    S                                    S                                    S                                    R                                    S                                    S                                    S                                    S                                     S                                     R                                     S                                     S                                     S                                     R                                     81.25   18.75
  AMI                                             S                                    S                                    S                                    S                                    S                                    R                                    S                                    S                                    S                                    S                                     S                                     S                                     S                                     S                                     S                                     R                                     87.5    12.5
  EST                                             S                                    S                                    S                                    R                                    S                                    R                                    S                                    R                                    S                                    S                                     S                                     R                                     S                                     S                                     R                                     R                                     62.5    37.5
  NEO                                             S                                    R                                    R                                    S                                    S                                    R                                    R                                    R                                    S                                    S                                     S                                     R                                     S                                     S                                     S                                     R                                     56.25   43.75
  POL                                             R                                    S                                    S                                    S                                    S                                    R                                    S                                    S                                    S                                    R                                     S                                     S                                     S                                     S                                     S                                     S                                     81.25   18.75
  IMI                                             S                                    S                                    S                                    S                                    S                                    S                                    S                                    S                                    S                                    S                                     S                                     S                                     S                                     S                                     S                                     S                                     100     0

Drugs: ENO: enrofloxacin; CIP: ciprofloxacin; NOR: norfloxacin; GAT: gatifloxacin; TOB: tobramycin; GEN: gentamicin; AMI: amikacin; EST: streptomycin; NEO: neomycin; POL: polymyxin B; IMI: imipenem. Susceptibilities: (S): susceptible; (R): resistant.

Strain isolated from dog.

Strain isolated from cat.

Strain isolated from horse.

Strain isolated from penguin.

Strain isolated from black bear.

Four strains of *P. aeruginosa* were resistant to ciprofloxacin: An isolate from a dog with corneal ulcer and oronasal fistula (sample 1), another isolate from a dog with keratoconjunctivitis sicca (sample 6), an isolate from cat with a corneal ulcer (sample 11), and an isolate from a horse with a deep corneal ulcer (sample 16). Five strains were resistant to tobramycin: The sample from a dog with corneal ulcer and oronasal fistula (sample 1), one from a dog with keratoconjunctivitis sicca (sample 6) three two from horses with corneal ulcers (sample 12 and 16 respectively), and one from a cat with corneal ulcer (case 11).

[Table 3](#T3){ref-type="table"} summarizes the MIC (µg/ml) results to ciprofloxacin and tobramycin of all 16 strains of *P. aeruginosa*. According to the CLSI (2013) MIC breakpoints, four isolates presented MIC values that demonstrated resistance to ciprofloxacin. Four isolates were resistant to tobramycin (same were resistant to ciprofloxacin). The four resistant strains were recovered from a dog (corneal ulcer; case 1), dog (KCS; case 6), a cat (corneal ulcer, case 11) and a horse (corneal ulcer, case 16).

###### 

Minimum inhibitory concentration (MIC) of 16 strains of *P. aeruginosa* recovered from eyes of different species of animals.

  Sample                                CIP (µg/mL)^[a](#t3f1){ref-type="table-fn"}^   Sus.   TOB (µg/mL)^[a](#t3f1){ref-type="table-fn"}^   Sus.
  ------------------------------------- ---------------------------------------------- ------ ---------------------------------------------- ------
  1^[b](#t3f2){ref-type="table-fn"}^    4.00                                           R      8.00                                           R
  2^[b](#t3f2){ref-type="table-fn"}^    0.19                                           S      2.00                                           S
  3^[b](#t3f2){ref-type="table-fn"}^    0.13                                           S      2.00                                           S
  4^[b](#t3f2){ref-type="table-fn"}^    0.094                                          S      1.50                                           S
  5^[b](#t3f2){ref-type="table-fn"}^    0.25                                           S      0.25                                           S
  6^[b](#t3f2){ref-type="table-fn"}^    12.00                                          R      ≤256                                           R
  7^[b](#t3f2){ref-type="table-fn"}^    0.19                                           S      3.00                                           S
  8^[b](#t3f2){ref-type="table-fn"}^    0.38                                           S      4.00                                           S
  9^[b](#t3f2){ref-type="table-fn"}^    0.094                                          S      1.00                                           S
  10^[b](#t3f2){ref-type="table-fn"}^   0.094                                          S      1.00                                           S
  11^[c](#t3f3){ref-type="table-fn"}^   2.00                                           R      32.00                                          R
  12^[d](#t3f4){ref-type="table-fn"}^   0.094                                          S      1.50                                           S
  13^[d](#t3f4){ref-type="table-fn"}^   0.094                                          S      1.00                                           S
  14^[e](#t3f5){ref-type="table-fn"}^   0.094                                          S      1.50                                           S
  15^[f](#t3f6){ref-type="table-fn"}^   0.094                                          S      1.00                                           S
  16^[d](#t3f4){ref-type="table-fn"}^   ≤32                                            R      ≤256                                           R

Drugs: CIP, ciprofloxacin (S≤1; I 2; R≥4); TOB, tobramycin (S≤4; I 8; R≥16). Sus: Susceptibilities; S: susceptible; R: resistant.

Strain isolated from dog.

Strain isolated from cat.

Strain isolated from horse.

Strain isolated from penguin.

Strain isolated from black bear.

In general MIC values for tobramycin were higher than for ciprofloxacin for all strains of *P. aeruginosa* evaluated. MIC values for ciprofloxacin varied from 0.13µg/ml to 32 µg/ml and the average MIC value was 3.24 ± µg/ml. MIC~90~ of ciprofloxacin was 3 µg/ml and MIC~50~ was 0.94 µg/ml. MIC values for tobramycin varied from 0.25 µg/ml to 256 µg/ml. The average MIC value was 35.76 µg/ml. The MIC~90~ was 48 µg/ml and the MIC~50~ was 1.50 µg/ml.

Discussion {#sec1-4}
==========

Animals, especially dogs, are well known naturally-occurring *P. aeruginosa* ulcerative keratitis models. The infection is considered appropriate for comparative investigations since this bacterial agent in canine infections is congruent with the classic genotype-phenotype pattern reported for human corneal isolates (Ledbetter *et al.*, 2009).

*P. aeruginosa* strains isolated from ocular infections have a particularly important role when prior ocular surface disease provides an opportunity for colonization and stabilization of an eye infection.

These conditions include keratoconjunctivitis sicca, corneal ulcers, chronic conjunctivitis and dental problems combined with infraorbital fistulas (Moore *et al.*, 1995; Ledbetter *et al.*, 2009; Wada *et al.*, 2010). The majority of these primary conditions were observed in the eyes of subjects in the present study ([Table 1](#T1){ref-type="table"}). Treatment with antibiotics effective against Gram-negative bacteria is usually successful. However, in some cases emergence of strains resistant to available antibiotics makes treatment difficult and poses as a real threat to an eye (Wada *et al.*, 2010).

A low *in vitro* susceptibility rate (25%) was observed for enrofloxacin against *P. aeruginosa* isolated from ocular tissues. This result was also observed by other authors while researching strains of *P. aeruginosa* from cases of keratitis in cats and dogs (Lin and Petersen-Jones, 2007, 2008). Conversely, the *in vitro* action of norfloxacin against *P. aeruginosa* was considered good since only three strains were resistant, one from a dog and two from horses. Another study investigating strains from dogs with septic keratitis also found good susceptibility rates for this drug, since only one strain (1/27) was resistant (Lin and Petersen-Jones, 2007). Ciprofloxacin demonstrated a satisfactory degree of *in vitro* activity against *P. aeruginosa* (75% susceptible strains) and four resistant strains were detected. Lin and Petersen-Jones (2007) encountered high *in vitro* susceptibility of this drug against *P. aeruginosa*, where 95% of the isolates from dogs with corneal ulcers were susceptible. In another investigation (Lin and Petersen-Jones, 2008), *P. aeruginosa* isolates from ulcerative keratitis of cats showed an even better result, with 100% of the strains being susceptible to ciprofloxacin. The fourth-generation fluorquinolone tested here, gatifloxacin, also showed a good *in vitro* susceptibility against *P. aeruginosa*, since three strains demonstrated resistance (81.5%). Another report (Ledbetter *et al.*, 2007) found 100% of strains from ulcerative keratitis in dogs susceptible for gatifloxacin. Compared with earlier generations, fourth-generation fluoroquinolones have an expanded spectrum of activity against Gram-positive bacteria, anaerobic bacteria, mycobacteria, and species of *Chlamydia*, *Chlamydophila*, *Mycoplasma*, and *Ureaplasma* (Moore *et al.*, 1995; Kowalski *et al*, 2003; Ledbetter *et al.*, 2007). Gram-negative bacterial spectrum of the third- and fourth-generation fluoroquinolones is preserved. However, compared with earlier generations (especially ciprofloxacin), they are less active *in vitro* against many Gram-negative bacteria, including *P. aeruginosa* (Kowalski *et al*, 2003; Ledbetter *et al.*, 2007). Therefore, even though there is a mass marketing pressure for clinicians to prescribe newer antibiotic drugs it is noteworthy that according to the literature (Jensen *et al.*, 2005) and the results presented in this study, there was no difference between the *in vitro* activity of gatifloxacin (fourth generation) and ciprofloxacin (second generation fluoroquinolone) against strains of *P. aeruginosa*; all strains that were resistant to ciprofloxacin, were also resistant to gatifloxacin.

Four pseudomonas strains isolated in this study demonstrated resistance to at least one of the aminoglycosides tested here. A total of 87.5% were susceptible to amikacin, 81.5% to gentamicin and 68.7% to tobramycin. Hariharan *et al*. (1995) found that 100% of pseudomonas strains from dogs were susceptible to tobramycin and amikacin, and 95% to gentamicin. Lin and Petersen-Jones (2008) found high susceptibility *in* *vitro* rates for amikacin (100%), tobramycin (80%) and gentamicin (75%) isolated from dogs with keratitis. Our results corroborate previous investigations of *P. aeruginosa* isolates indicating that these drugs are still effective. Aminoglycosides are an important antibiotic group available in veterinary ophthalmic formulations. When compared with another bacterial genera frequently isolated from animal eyes, e.g. *Staphylococcus*, gentimicin and tobramycin are not very effective (47.5% of the strains were resistant to gentamicin and 65% were resistant to tobramycin) (Varges *et al.*, 2009). This confirms the importance of identifying the specific pathogen in a given bacterial ocular surface disease and determining its respective sensitivity pattern. The use of topical amikacin has been suggested as a better empiric alternative to gentamicin or tobramycin (Hariharan *et al.*, 1995). In our results, two strains that were resistant to tobramycin were susceptible for amikacin (cases n° 11 and 12) and two strains were resistant to all aminoglycosides tested (cases n° 6 and 16). The appearance of strains resistant to amikacin is of some concern since this drug is one of the most useful agents for treatment of severe *P. aeruginosa* infections (Hariharan *et al.*, 1995).

In this investigation, 56.5% of the strains were susceptible to neomycin, similar to the susceptibility reported in another study of *P*. *aeruginosa* isolates from feline ulcerative keratitis (63%) (Lin and Petersen-Jones, 2008). Neomycin is commonly prescribed in combination with bacitracin and polymyxin B for topical therapy of eye infections in triple antibiotic formulations. Triple antibiotic formulations maximize the spectrum of antibacterial activity against both Gram-positive and Gram-negative bacteria. *Pseudomonas* spp. is often resistant to neomycin, but polymixin B is rapidly bactericidal against Gram-negative bacteria, including *P. aeruginosa* (Lima Filho and Batistuzzo, 2006). In our study, 81% of *P. aeruginosa* were susceptible *in vitro* to polymixin B. However, previous studies have conflicting results, ranging from 100% susceptibility of veterinary isolates (Hariharan *et al.*, 1995) to susceptibility rates as low as 40% (Ledbetter *et al.*, 2009). We also observed that nearly all strains that were resistant neomycin were susceptible to polymixin B, or vice-versa. Thus, our *in vitro* results corroborate the clinical recommendation for this triple antibiotic combination to be used as a first choice option for treatment of ocular surface *P. aeruginosa* infections (Maggs, 2008).

No isolates tested in this study were resistant to imipenem. The carbapenems antibiotics are commonly used in human multi-resistant pseudomonas infections. The lack of apparent resistance of *P. aeruginosa* strains to imipenem should be highlighted, especially when compared to those findings obtained from cases of human *P. aeruginosa* isolates, in which the *in vitro* resistance can reach 4% (Mohammadpour *et al.*, 2011) to 40% (Fernandes *et al.*, 2015). Although this drug is rarely used in veterinary medicine and is not approved for use in animals by the Food and Drug Administration, veterinarians can legally prescribe imipenem as an extra-label drug for ocular infections consisting of multi-resistant strains of *P. aeruginosa*. Although use of intravenous imipenem preparations topically on the eye has been suggested for ocular infections with multi-resistant *P. aeruginosa* strains, the high price, instability of imipenem solutions \[it should be used within 48 hours and kept under refrigeration (Lima Filho and Batistuzzo, 2006)\], and debate about reservation for human use make it a rare treatment choice.

Based on this study, the best *in vitro* activities against *P*. *aeruginosa* isolated from animal´s eyes could be ranked as 1: imipenem, 2: amikacin, 3: gatifloxacin, norfloxacin, gentamicin or polymyxin. Imipenem and amikacin eye drops are only available in extemporaneous compounding formulations. Gatifloxacin, norfloxacin, gentamicin and polymyxin are commercially available in the form of eye drops in most countries.

Even with a small sample size of 16 positive *P. aeruginosa* cultures, this work presents interesting data. Notice that diagnoses include conjunctivitis and keratoconjunctivitis sicca, which are normally not primarily caused by *Pseudomonas*, but high resistant strains were isolated, could complicate or delay the disease resolution.

This investigation also determined the MIC values of two important antibiotics commercially available in the form of eye drops and commonly used in veterinary and medical ophthalmology: ciprofloxacin and tobramycin. *In* *vitro* resistance breakpoints are based on antibiotic concentrations in the blood (CLSI, 2013). However, because ocular antibiotics can reach higher concentrations, this breakpoint does not truly represent bacterial resistance in the eye. Ocular antibiotics will most likely have a higher resistance breakpoint value than systemic antibiotics. For example, a 1% drop with a concentration of 10 µg/mL results in a concentration of 10.000 µg/mL on the eye. Alternatively, in the serum, tissues, or blood, the level may only be 10 µg/mL when the same drug is administered orally (Mah, 2003). Therefore, bacteria identified as resistant elsewhere in the body (e.g. lung) may respond differently if located in the eye and are exposed to topical antibiotic. Studies conducted by Kaye *et al*. (2009) showed that topical administration of an antimicrobial to the cornea may achieve a different concentration and bioavailability in the tissue than the serum levels. In the treatment of bacterial keratitis, the MIC values are an important measure for evaluating the potential effectiveness of topically applied antimicrobials (Sueke *et al.*, 2010).

Both tobramycin and ciprofloxacin formulated as eye drops have a concentration of 3mg/mL in commercially available solutions (Peiffer and Stowe, 1981; Viana, 2007). If one drop (approximately 0.05 mL as commercially droppers delivery a 25 a 50 µL/drop of solution or suspension), is instilled into the eye, the solution maintains a good antibiotic concentration (0.15 mg). Knowing that the conjunctival fornix of the eye will hold only one drop (Peiffer and Stowe, 1981) (which means 0.05mL) and only 10 to 25 µL of drug are retained in the conjunctival fornix and tear film (Peiffer and Stowe, 1981; Viana, 2007), the concentration of the drugs still will be at 75 µg.

The MIC values found for ciprofloxacin in this study ranged from 0.094 to 32 µ/mL, so, for this drug, the amount present in the conjunctival fornix, exceed the MIC of the strains tested. For tobramycin, the MIC ranged from 0.25 to 256 µg/mL. One MIC isolate tested was 48 µg/mL (case n°11) and two others (cases n° 6 and 16) exceed the MIC (256 µg / mL) of this antibiotic, and for this isolate, the use of eye drops might not be medically effective. A study conducted in ophthalmology centers in the United Kingdom demonstrated the MICs for *P*. *aeruginosa* isolated from human keratitis ranged from 0.016 to 6.000 mg/L (Sueke *et al.*, 2010).

The average concentration of antibiotics in tears may vary. For ciprofloxacin (0.3% ophthalmic solution) 4 hours after instillation, tear concentration becomes 16 µg/mL in human beigns (Limberg and Buggé, 1994) and 36.25 µ/mL for horses (Hendrix *et al.*, 2007). Considering that the MIC of the strains tested in this study did not exceed 12 µg/mL, the concentration of this drug in tears within four hours is still most likely higher, so instillation of one drop of ciprofloxacin is effective if repeated every four hours.

One study (Tang-Liu *et al.*, 1994) showed that 4 hours after instillation, tobramycin has an average concentration of 8µg/mL in human tears. Therefore, this concentration would still be effective against most strains tested in this study, since most strains had an MIC of 1.00 µg/mL. However, four strains obtained higher MICs (8 µg/mL, 48 µg/mL and two isolated with 256 µg/mL). These MICs suggest poor response to treatment *in vivo* with tobramycin considering the possible MICs that can be achieved in the most common eye drop treatment protocols. Therefore, it is recommended to increase the frequency of administering tobramycin from every four to approximately every two hours.

MIC at the site of a *P. aeruginosa* ocular surface infection must reach high concentrations in order to be effective. The evaluation of *P. aeruginosa* susceptibility by microbiology laboratories is typically made with reference to concentrations in human serum. However, concentrations of antibiotics obtained from the ocular surface by local application of eye drops or ointments are higher, and it is important to determine the MIC to better assess the antibiotic susceptibility of specific bacterial strains isolated from ocular surface infections.

Our study revealed that the antimicrobials with the best *in vitro* actions against *P*. *aeruginosa* isolated from the eyes of selected animals from Brazil were 1: imipenem, 2: amikacin, 3: gatifloxacin, norfloxacin, gentamicin or polymyxin. This study also showed that commercially available concentrations of ciprofloxacin eye drops used for local treatment (3 mg/ml) was effective against all strains tested in this study if applied up to 4 hours after instillation. For tobramycin eye drops as commercially presentation the concentrations of 3mg/ml, however, cannot reach an ideal MIC for some resistant strains with. Thus for ocular surface infections with *P. aeruginosa* when using tobramycin the ideal recommendation would be to either to use eye drops with higher concentrations or decrease the frequency intervals from four hours to a minimum of every two hours.
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